Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Alx Oncology Holdings (ALXO) Interest Expenses (2019 - 2023)

Alx Oncology Holdings' Interest Expenses history spans 4 years, with the latest figure at $415000.0 for Q4 2023.

  • For Q4 2023, Interest Expenses rose 79.65% year-over-year to $415000.0; the TTM value through Dec 2023 reached $1.6 million, up 557.56%, while the annual FY2025 figure was $1.6 million, 7.35% down from the prior year.
  • Interest Expenses for Q4 2023 was $415000.0 at Alx Oncology Holdings, up from $391000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $415000.0 in Q4 2023 and bottomed at -$5000.0 in Q4 2020.
  • The 4-year median for Interest Expenses is $117000.0 (2022), against an average of $175500.0.
  • The largest annual shift saw Interest Expenses crashed 600.0% in 2020 before it surged 19450.0% in 2023.
  • A 4-year view of Interest Expenses shows it stood at $1000.0 in 2019, then plummeted by 600.0% to -$5000.0 in 2020, then surged by 4720.0% to $231000.0 in 2022, then soared by 79.65% to $415000.0 in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Interest Expenses are $415000.0 (Q4 2023), $391000.0 (Q3 2023), and $372000.0 (Q2 2023).